Form 4: vTv Therapeutics Director Daniel K. Spiegelman Granted 4,000 Stock Options

vTv Therapeutics Inc. Director Daniel K. Spiegelman was granted 4,000 stock options with an exercise price of $16.59, which will vest by June 2026.

Summary

• Daniel K. Spiegelman, a Director of vTv Therapeutics Inc. (VTVT), was granted 4,000 director stock options on June 10, 2025.
• The options have an exercise price of $16.59 per share.
• These options will vest on the earlier of June 10, 2026, or the date of the 2026 annual general meeting of shareholders, contingent on Mr. Spiegelman's continued service on the board.
• The options have an expiration date of June 10, 2035.
• Following this transaction, Daniel K. Spiegelman beneficially owns 10,000 derivative securities (stock options).

Sentiment

Score: 6

Explanation: The sentiment is mildly positive as it represents a standard compensation practice that aligns director interests with shareholders, indicating continued engagement and confidence, but it is a routine transaction not indicative of significant new developments.

Positives

• The grant of stock options to a director aligns their interests with those of shareholders, as the value of the options increases with the company's stock price.
• This transaction represents a standard form of equity compensation for board members, indicating ongoing commitment and incentivization for long-term performance.

Future Outlook

The vesting schedule for the options indicates a future milestone for the director's equity compensation, aligning with the company's 2026 annual general meeting of shareholders.

Industry Context

The grant of stock options to directors is a common practice in the biotechnology and pharmaceutical industries, including companies like vTv Therapeutics, to attract and retain experienced board members and align their long-term incentives with shareholder value creation.

Comparison to Industry Standards

• Granting stock options as part of director compensation is a standard practice across various industries, including biotech, to incentivize long-term performance and align interests.
• The specific number of options (4,000) and the exercise price ($16.59) would typically be benchmarked against compensation packages for directors at peer companies of similar size and stage of development within the pharmaceutical sector, though specific comparable companies or projects are not detailed in this filing.

Related Party Transactions

• The grant of 4,000 stock options to Daniel K. Spiegelman, a Director of vTv Therapeutics Inc., constitutes a related party transaction as it involves compensation provided by the company to a member of its board of directors.

Stakeholder Impact

• Shareholders: The grant of options can align the director's interests with shareholders by incentivizing stock price appreciation. However, future exercise of these options could lead to minor dilution.
• Employees: No direct impact mentioned, but it reinforces the company's compensation structure for leadership.

Next Steps

• The options will vest on the earlier of June 10, 2026, or the date of the 2026 annual general meeting of shareholders, subject to continued service.

Key Dates

Keywords

vTv Therapeutics, VTVT, SEC Form 4, stock options, director compensation, insider transaction, equity grant